Published in Heliyon on April 11, 2017
The hallmarks of cancer. Cell (2000) 113.05
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Cancer genome landscapes. Science (2013) 25.33
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer (2004) 3.50
Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics (2010) 2.52
Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer (1998) 2.06
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget (2012) 2.03
Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet (2014) 1.94
The mutation rate and cancer. Genetics (1998) 1.88
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer (2009) 1.70
The cellular, developmental and population-genetic determinants of mutation-rate evolution. Genetics (2008) 1.69
Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A (1998) 1.55
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res (2012) 1.47
RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases. Gastric Cancer (2015) 1.45
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer (2006) 1.41
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet (2015) 1.36
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer (2013) 1.36
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24
Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol (2009) 1.23
Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. Am J Respir Cell Mol Biol (2009) 1.22
The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One (2013) 1.22
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene (2011) 1.21
The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One (2011) 1.20
Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Res (2006) 1.19
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6. Carcinogenesis (2006) 1.19
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res (2011) 1.17
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene (2010) 1.16
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer (2014) 1.13
Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. J Cancer (2011) 1.09
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Mol Cancer (2010) 1.06
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J (2015) 1.05
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol (2013) 1.04
ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol (2013) 1.04
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst (2014) 1.03
Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn (2010) 1.02
Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer (2010) 1.02
A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer (2009) 1.02
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep (2015) 1.02
MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol (2013) 1.01
DriverDB: an exome sequencing database for cancer driver gene identification. Nucleic Acids Res (2013) 0.99
Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status. Med Sci Monit Basic Res (2014) 0.98
Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma. Oncol Lett (2011) 0.98
Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One (2014) 0.98
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res (2012) 0.98
NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol Endocrinol (2014) 0.96
Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis. Hum Mol Genet (2004) 0.95
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet (2015) 0.95
Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. BMC Cancer (2012) 0.95
SPOP mutation leads to genomic instability in prostate cancer. Elife (2015) 0.93
Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol (2011) 0.93
Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol Oncol (2009) 0.93
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. Oncotarget (2015) 0.92
The Synergistic Effect of Conditional Pten Loss and Oncogenic K-ras Mutation on Endometrial Cancer Development Occurs via Decreased Progesterone Receptor Action. J Oncol (2009) 0.91
Estimating mutant microsatellite allele frequencies in somatic cells by small-pool PCR. Genomics (2004) 0.91
High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One (2012) 0.91
Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget (2015) 0.90
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. J Natl Cancer Inst (2015) 0.90
Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS One (2013) 0.90
Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer. Mol Med Rep (2015) 0.90
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate (2015) 0.90
Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One (2012) 0.90
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. Mod Pathol (2009) 0.89
IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget (2015) 0.89
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene (2015) 0.89
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet (2000) 0.89
Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells (2010) 0.89
Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer (2005) 0.88
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One (2014) 0.88
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. Int J Clin Exp Pathol (2014) 0.88
Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells. Mutat Res (2005) 0.87
Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß. PLoS One (2013) 0.87
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer (2012) 0.87
High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget (2015) 0.87
PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. PLoS One (2016) 0.87
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther (2013) 0.87
Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment. J Cancer (2012) 0.86
Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol (2009) 0.86
A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland. Proc Natl Acad Sci U S A (2009) 0.86
Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer (2015) 0.85
Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma. Exp Cell Res (2011) 0.85
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One (2014) 0.85
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer (2015) 0.84
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications. Breast Cancer Res (2012) 0.84
The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer. PLoS One (2015) 0.84